SWiss Atorvastatin and interferon Beta-1b trial In Multiple Sclerosis (SWABIMS)--rationale, design and methodology
| Data(s) |
2009
|
|---|---|
| Resumo |
Statins have anti-inflammatory and immunomodulatory properties in addition to their lipid-lowering effects. Currently, the effects of statins on multiple sclerosis are still controversial. Therefore, randomized clinical trials are needed to provide better evidence on the therapeutic potential of statins in multiple sclerosis. The SWiss Atorvastatin and Interferon Beta-1b trial in Multiple Sclerosis (SWABIMS) evaluates the efficacy, safety and tolerability of atorvastatin 40 mg per os daily and subcutaneous interferon beta-1b every other day compared to monotherapy with subcutaneous interferon beta-1b every other day in patients with relapsing-remitting multiple sclerosis. |
| Formato |
application/pdf |
| Identificador |
http://boris.unibe.ch/32430/1/1745-6215-10-115.pdf Kamm, Christian P; Mattle, Heinrich P (2009). SWiss Atorvastatin and interferon Beta-1b trial In Multiple Sclerosis (SWABIMS)--rationale, design and methodology. Trials, 10, p. 115. London: BioMed Central 10.1186/1745-6215-10-115 <http://dx.doi.org/10.1186/1745-6215-10-115> doi:10.7892/boris.32430 info:doi:10.1186/1745-6215-10-115 info:pmid:20003436 urn:issn:1745-6215 |
| Idioma(s) |
eng |
| Publicador |
BioMed Central |
| Relação |
http://boris.unibe.ch/32430/ |
| Direitos |
info:eu-repo/semantics/restrictedAccess |
| Fonte |
Kamm, Christian P; Mattle, Heinrich P (2009). SWiss Atorvastatin and interferon Beta-1b trial In Multiple Sclerosis (SWABIMS)--rationale, design and methodology. Trials, 10, p. 115. London: BioMed Central 10.1186/1745-6215-10-115 <http://dx.doi.org/10.1186/1745-6215-10-115> |
| Tipo |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion PeerReviewed |
